This website is a non-promotional global resource intended to facilitate transparent scientific exchange regarding developments in medical research, diagnostics, and disease management.
Not a healthcare professional? Browse:
This website is a non-promotional global resource intended to facilitate transparent scientific exchange regarding developments in medical research, diagnostics, and disease management. This global website is intended for healthcare professionals outside the UK, US, Canada, and Australia. The content on this website may include scientific information about experimental or investigational compounds, indications, and services that are not approved or valid in your country. Registration status and prescribing information of medicinal products may differ between countries. Please refer to local product information for any medicinal products mentioned on this website. Information available on this website does not constitute professional medical advice, and Roche and Genentech accept no responsibility for access to or use of the same.
You are Leaving Medically
By following this link, you are leaving Roche Website and entering a site that is not owned or controlled by Roche. Roche does not take any responsibility for acces to or use of this website, nor for any content therein.
You are Leaving the Global Medically Site
By following this link, you are being redirected to another Roche page.
What's new
Congresses & Events
14 April, 2025
Congresses & Events
11 April, 2025
Congresses & Events
8 April, 2025
Updated efficacy and safety data, and new patient-reported preference data are presented from the OCARINA II study.
Congresses & Events
8 April, 2025
Updated efficacy and safety data, and new patient-reported preference data are presented from the OCARINA II study.
Congresses & Events
8 April, 2025
This analysis assessed the efficacy, safety and exploratory biomarkers, such as immunoglobulins and B cells, after fenebrutinib treatment in people with RMS enrolled int he FENopta open-label extension through Week 48.
Congresses & Events
7 April, 2025
The long-term extension of this longitudinal study of ocrelizumab treatment in people with relapsing multiple sclerosis evaluated cerebrospinal fluid levels of neurofilament light chain, CD19+ B cells and CD3+ T cells up to 240 weeks.
Congresses & Events
7 April, 2025
Several states are considering policies to address concerns about patient affordability of drugs, including examining the impact of health plan benefit design on patient financial liability. ● Commercial health plans fall typically into one of two categories: fully insured (FI) plans (state-regulated) and self-funded (SF) plans (federally regulated). ● Employers who choose to self-fund have more control over their benefits; however, little is known about how benefit designs and patient cost sharing differ between SF and FI health plans.
Congresses & Events
7 April, 2025
Copay assistance programs reduce patients’ out-of-pocket costs for medications, which can lead to improved clinical and more equitable outcomes.1,2 – However, it is believed that these programs may lead to higher medication prices.3 – Despite this belief, there is limited real-world evidence of the association between copay assistance utilization and medication prices.
Congresses & Events
7 April, 2025
MINORE is a prospective Phase IV, open-label study measuring placental transfer of ocrelizumab and potential impact on newborn B-cell levels, with detailed maternal and infant clinical outcomes, humoral immunity, safety and serum biomarkers. SOPRANINO is the first prospective study measuring pharmacodynamic and pharmacokinetic parameters of ocrelizumab in breastmilk and potential effects on infant humoral response to vaccines, safety, growth and development.
Congresses & Events
7 April, 2025
This presentation reports key findings from the RHONE-X extension trial that demonstrated the long-term safety and efficacy of faricimab▼ treat & extend in patients with DME who rolled over from the YOSEMITE and RHINE clinical trials. BCVA gains and CST improvements from parent trials were maintained in RHONE-X, with approximately 80% of patients on ≥ Q12W faricimab▼ dosing intervalsand >90% patients achieved absence of DME by the end of the trial.
Ask us a question and request information about Roche products or services.
If you have experienced potential side effects with a Roche product you can report it here.
If you suspect a potential defect or a Roche product has not met your expectations you can report it here.
Request an assessment if your product was stored outside the recommended temperature range.
On this global platform you will find tailored, evidence-based, balanced, and up-to-date medical information from Roche.This website is intended to provide medical information relating to questions asked about Roche medicines.
This website is not country specific and therefore may contain medical information on Roche medicines that is not applicable to your country. Please refer to your country prescribing information and local package insert.
Some medical information contained on this site may not be consistent with the locally approved indications for the specific Roche medicine. If you are a patient on a Roche medicine, please contact your treating doctor for medical support and before making any changes to your treatment.